ViraPap: can it help to reduce the need for colposcopy?
Two new tests recently became available for identifying cervical human papillomavirus (HPV). This study investigated the usefulness of the ViraPap and ViraType in the clinical setting. Thirty-six subjects considered to be at risk for HPV infection were examined; had specimens obtained for Papanicolaou smear (Pap smear), ViraPap, and ViraType; and were then referred for colposcopy. Results of these examinations were then compared to the findings of colposcopy and/or colposcopic biopsy. The sensitivity and specificity of the ViraPap in predicting an abnormality being found on colposcopic examination were 61.5% and 70%, respectively. Identifying the specific viral type by use of the ViraType did not prove to be clinically helpful in this population.
Mareck
D G
DG
University of South Dakota Health Clinic, Vermillion.
Woolard
D G
DG
D000293:Adolescent; D000328:Adult; D001706:Biopsy / Q000592:standards; D003127:Colposcopy / Q000592:standards; D015342:DNA Probes / Q000592:standards; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000592:standards; D065006:Papanicolaou Test; D027383:Papillomaviridae; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012680:Sensitivity and Specificity; D012703:Serotyping; D014412:Tumor Virus Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D002577:Uterine Cervical Diseases / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D014626:Vaginal Smears / Q000592:standards
D015342:DNA Probes; D011933:Reagent Kits, Diagnostic